Outcomes of adjunctive therapy with intravenous cefoperazone-sulbactam for ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii

Siripen Kanchanasuwan, Narongdet Kositpantawong, Kamonnut Singkhamanan, Thanaporn Hortiwakul, Boonsri Charoenmak, Ozioma F. Nwabor, Yohei Doi, Sarunyou Chusri

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The efficacy of adjunctive therapy with cefoperazone-sulbactam (CEP-SUL) for ventilator-associated pneumonia (VAP) due to carbapenem-resistant A. baumannii (CRAB) is unclear. Methods: We retrospectively analyzed the therapeutic effect of adding CEP-SUL to standard regimens for VAP due to CRAB. Patients with VAP due to CRAB strains that were susceptible to CEP-SUL were enrolled into the study. The patients were divided into two groups: Those who receive cefoperazone-sulbactam (CEP-SUL+), and those who did not receive cefoperazone-sulbactam (CEP-SUL). Mortality rates and resource utilization of these two groups were compared. Factors associated with mortality were explored. Results: Eighty patients were enrolled into the study, 52 CEP-SUL+ and 28 CEP-SUL. The baseline characteristics of the two groups were comparable, except for median Acute Physiology and Chronic Health Evaluation (APACHE) II score which was significantly higher for CEP-SUL+. Thirty-day, and in-hospital mortality rates for CEP-SUL+ were significantly lower than CEP-SUL with values of 35%, 39% and 61%, 68%, for CEPSUL+ and CEP-SUL, respectively. The survival rate for CEP-SUL+ was significantly higher compared with CEP-SUL (P < 0.001). The number of hospital days, ventilator days since diagnosis of VAP and hospital costs were lower for CEP-SUL+. Conclusion: Overall results suggested that patients with VAP due to CRAB strains who received adjunctive therapy with CEP-SUL had lower mortality rates and resource utilization compared with CEP-SUL.

Original languageEnglish
Pages (from-to)1255-1264
Number of pages10
JournalInfection and Drug Resistance
Volume14
DOIs
Publication statusPublished - 2021

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Outcomes of adjunctive therapy with intravenous cefoperazone-sulbactam for ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii'. Together they form a unique fingerprint.

Cite this